Switching from tafamidis to acoramidis for heart condition
Treatments studied
Part of Heart & circulation clinical trials.
This study checks how levels of a protein called transthyretin change in your blood when you switch from tafamidis to acoramidis. It is for people with a specific type of heart disease caused by abnormal protein buildup.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You have been diagnosed with transthyretin amyloidosis with cardiomyopathy (heart muscle problems from protein buildup).
- You are currently taking tafamidis and have been on it for at least the last 3 months.
- You have mild or no heart failure symptoms (NYHA class I or II).
- Your kidney function is at least 30 mL/min (eGFR) and your NT-proBNP level is between 300 and 7000 pg/mL.
- You have not had a heart or liver transplant, a heart device, recent heart attack or surgery, or dialysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
This trial tests a new medicine called acoramidis for people with a heart condition caused by a protein called transthyretin. It includes people who are newly diagnosed or who are already taking another drug (tafamidis) and may benefit from switching. The goal is to see how well acoramidis works and how it affects heart-related measures.
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
This study is testing a medication called acoramidis for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It aims to see how well the treatment works in a real-world setting in France.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study looks at the long-term safety of the study drug acoramidis for people living with a heart condition called ATTR-CM. It may help doctors understand the long-term effects and benefits of this treatment.
Hear when a new Transthyretin Amyloid Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.